Developing GA101, A Humanized Anti-CD20 Monoclonal Antibody With Hematological Malignancies Potential Treatment - Genentech, GlycArt And Roche Collabo
Oct 3rd 2008Drug InformationCancer
Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt’s GA101 molecule.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
